Wanbury Reports Strong Financial Growth Amid Rising Interest Costs in May 2025 Results

Wanbury, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 15, 2025, indicate a notable shift in the company's evaluation, with a revision in its score reflecting a positive trajectory over the past three months.
The financial data reveals significant growth in key metrics. Profit Before Tax less Other Income (PBT) reached Rs 17.21 crore, marking a substantial increase compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) stood at Rs 20.26 crore, showcasing a strong upward trend. The company also reported its highest net sales in five quarters at Rs 172.00 crore, indicating robust sales performance.

Additionally, Wanbury's operating profit margin improved to 17.22%, highlighting enhanced operational efficiency. However, the company faces challenges, including rising interest costs, which have increased by nearly 26% over the preceding nine months, suggesting higher borrowings. Furthermore, while non-operating income reached its highest level in five quarters, its sustainability remains uncertain.

Overall, Wanbury's recent financial results reflect a complex landscape of growth and challenges, leading to adjustments in its evaluation.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.